EGFR and non-small cell lung carcinoma: Although currently licensed EGFRi have not shown any significant benefit for patients with other EGFR exon 20 insertions, emerging EGFRi including poziotinib, TAK-788 and tarloxotinib are in clinical development with promising activity for this subgroup of NSCLC patients.